We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 136

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

Northern exposure?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Supplemental protection certificates (SPCs): the search for clarity goes on when is a marketing authorisation to be relied on?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 25 2013

In another attempt to clarify the basic criteria for SPC eligibility, Mr. Justice Arnold has referred AstraZeneca AB v Comptroller-General 2012

New Canadian Patent Office guidelines for computer-related inventions

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 14 2013

On March 8, 2013 the Canadian Intellectual Property Office (CIPO) released two related practice notices (PN2013-02 and PN2013-03) in response to the

Court affirms utility of Gleevec patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J

Patents year in review 2012

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 8 2013

In 2012, the Supreme Court of Canada handed down its landmark decision clarifying the law of sufficient disclosure and serving notice that “gaming the

Canada expands options for accelerating patent prosecution

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 6 2013

On January 31, 2013, the Canadian Intellectual Property Office (CIPO) commenced a two-year pilot Patent Cooperation Treaty-Patent Prosecution Highway

Generic damages in life sciences patent litigation: strategic considerations

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 31 2013

In this presentation, Christopher Van Barr and Kiernan Murphy discuss strategic considerations relating to generic damages in life sciences patent

Ontario Court denies generic claims for innovator profits: Apotex v. Takeda and Abbott, 2013 ONSC 356

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 24 2013

On January 15, 2013, a provincial Court held, for the first time, that generic drug companies are prohibited from claims of disgorgement of an

European unitary patent: what does it mean for Canadians?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • December 17 2012

On December 11, 2012, the European Parliament approved a legislative package that is aimed at establishing a single, unified European patent system

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy